恒瑞医药：子公司收到SHR-4298注射液药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-4298 injection, aimed at treating advanced solid tumors [1] Company Summary - SHR-4298 injection is a Class 1 therapeutic biological product independently developed by the company [1] - The total research and development investment for the related project has reached approximately 28.79 million yuan [1] - The drug must undergo clinical trials and receive further review and approval from the National Medical Products Administration before it can be produced and marketed [1] Industry Summary - The approval for clinical trials indicates a potential advancement in the treatment options available for advanced solid tumors within the biopharmaceutical industry [1] - The development of innovative therapies like SHR-4298 reflects ongoing investment and research efforts in the biopharmaceutical sector [1]